David Torrents, Oliver Hofmann, Karen Ann Cranston, Raffaella Casolino, Andrew V Biankin, Andrés F Cardona, Robert L Grossman, Amber Johns, Mark Lawler, Kjong-Van Lehmann, Raquel Manzano Garcia, Nicola Mulder, Travis Osterman, Timothy Rebbeck, Solomon Rotimi, Zbyslaw Sondka, Shawn Sweeney, Samuel Volchenboum, Alex Wagner, Jianmin Wu, Takayuki Yoshino, Mélanie Courtot, Lincoln Stein
{"title":"Cancer genomic data systems in precision oncology: from integration to clinical implementation.","authors":"David Torrents, Oliver Hofmann, Karen Ann Cranston, Raffaella Casolino, Andrew V Biankin, Andrés F Cardona, Robert L Grossman, Amber Johns, Mark Lawler, Kjong-Van Lehmann, Raquel Manzano Garcia, Nicola Mulder, Travis Osterman, Timothy Rebbeck, Solomon Rotimi, Zbyslaw Sondka, Shawn Sweeney, Samuel Volchenboum, Alex Wagner, Jianmin Wu, Takayuki Yoshino, Mélanie Courtot, Lincoln Stein","doi":"10.1016/j.ebiom.2026.106480","DOIUrl":null,"url":null,"abstract":"<p><p>Cancer genomic data sharing is a core pillar of precision oncology, underpinning reproducibility, scalability, and equity. The ability to discover, access, integrate, interpret, and reuse cancer 'omics data is a key determinant of precision oncology's value and benefit at scale. This work has been conducted as part of The Lancet Oncology Commission on Cancer Genomics and Precision Oncology to examine the practical data architecture required to support cancer genomics in research, clinical care, and health-system learning. We conclude that without robust data stewardship, including effective data sharing and global integration, the potential of cancer genomics will remain fragmented across projects, platforms, and jurisdictions. This disaggregation limits reproducibility, equity, patient benefit, and societal value. Healthcare systems must prioritise implementing fully efficient data ecosystems as a central challenge for precision oncology.</p>","PeriodicalId":11494,"journal":{"name":"EBioMedicine","volume":" ","pages":"106480"},"PeriodicalIF":11.2000,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13688039/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"EBioMedicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.ebiom.2026.106480","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/9/25 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0
Abstract
Cancer genomic data sharing is a core pillar of precision oncology, underpinning reproducibility, scalability, and equity. The ability to discover, access, integrate, interpret, and reuse cancer 'omics data is a key determinant of precision oncology's value and benefit at scale. This work has been conducted as part of The Lancet Oncology Commission on Cancer Genomics and Precision Oncology to examine the practical data architecture required to support cancer genomics in research, clinical care, and health-system learning. We conclude that without robust data stewardship, including effective data sharing and global integration, the potential of cancer genomics will remain fragmented across projects, platforms, and jurisdictions. This disaggregation limits reproducibility, equity, patient benefit, and societal value. Healthcare systems must prioritise implementing fully efficient data ecosystems as a central challenge for precision oncology.
EBioMedicineBiochemistry, Genetics and Molecular Biology-General Biochemistry,Genetics and Molecular Biology
CiteScore
17.70
自引率
0.90%
发文量
579
审稿时长
5 weeks
期刊介绍:
eBioMedicine is a comprehensive biomedical research journal that covers a wide range of studies that are relevant to human health. Our focus is on original research that explores the fundamental factors influencing human health and disease, including the discovery of new therapeutic targets and treatments, the identification of biomarkers and diagnostic tools, and the investigation and modification of disease pathways and mechanisms. We welcome studies from any biomedical discipline that contribute to our understanding of disease and aim to improve human health.